African-AmericansRace-Based Pharmaceutical DrugBiDil is the first drug admitted by the Food and Drug Administration for a single racial – ethnic group, African-Americans, approved marketed for the treatment of congestive heart failure. This analysis describes the background questions to prepare doctors advise patients about this controversial drug.

To to ‘ disaster, ‘ Editorial SaysAlthough action on issues such as the fight against HIV / AIDS and malaria worldwide, requires institutions, The Global Fund to Fight AIDS, Tuberculosis and Malaria is a mess , a Washington editorial editorial says. The Global Fund provides a fifth of all donor funding for AIDS, almost half of TB and two thirds for malaria and is central to the fight against the three diseases, according to the Post. Five years after Start, Richard Feachem, the Global Fund’s first managing director, is resignation, the editorial says, adding that in the past month , donor and recipient countries on the organization of the Board on the election of a successor stuck. in addition, the about the Global Fund about the Global Fund guidance through the uncertainty intensified about the business model, says the Post. The Global Fund started as an institutional experiment in the aid world, the editorial says, adding that it always overhead costs low by design solution for any program, instead of collecting and evaluating prepare funding requests from agencies in poor countries. Although the principle is attractive because the recipient feel a greater proportion of their success and better programs, the developing countries ‘ implementation of often require technical assistance, design programs design programs and the implementation headache to deal, says the Post. Until the Global Fund is achieved leadership until until the new leader finds the right balance between hands-off and hands-on, uncertain uncertain, says of the Global Fund finances, the editors. Although the Global Fund has paid a quick – start for a new agency and in the last five years, more than $ 3 billion to 136 countries, it needs to grow, the editorial says, adding that it has perhaps the half of the $ 8 billion per year , the supply is likely to be needed to meet the challenges of the three diseases, the editorial concludes: . Without this kind of boost, it will not enough money to the medical tools that already exist deploy, its its use of new discoveries (Washington Post.

But the with heart failure optimistically life expectancy of.